The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development
Vertex, one of biotech’s fastest-growing companies thanks to its success in developing ground-breaking cystic fibrosis therapies, grew its revenues by 50% last year to $6.2bn, and is coming under pressure to spend some of its cash pile on M&A.
The company is forecasting around 10% growth this year, based on expansion from its cystic fibrosis triple therapy Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor)...
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
